Dermal Cell News Volume 1.24 | Nov 16 2015

LPS-Stimulated Human Skin-Derived Stem Cells Enhance Neo-Vascularization during Dermal Regeneration
Stem cells derived from human skin were activated with lipopolysaccharide (LPS) and seeded in a commercially available dermal substitute to examine vascularization in vivo. [PLoS One] Full Article

Co-Transplantation of Skin-Derived Precursors and Collagen Sponge Facilitates Diabetic Wound Healing by Promoting Local Vascular Regeneration
Skin-derived precursors (SKPs) were isolated and transplanted directly to the wound areas of diabetic mice in the absence and presence of collagen sponge. Accelerated wound healing and enhanced local capillary regeneration could be observed 14 days after skin ablation from both SKPs and collagen sponge co-transplanted and collagen sponge only groups. [Cell Physiol Biochem] Full Article

Healing of Skin Wounds with a Chitosan-Gelatin Sponge Loaded with Tannins and Platelet-Rich Plasma
A chitosan-gelatin sponge (CSGT) was prepared using a chitosan/ascorbic acid solution blend containing gelatin, followed by crosslinking with tannin acid and freeze-drying, thereby combining the chitosan sponge and gelatin sponge. The CSGT and the CSGT with platelet-rich plasma were suitable for application as a wound dressing. [Int J Biol Macromol] Abstract

Exacerbated and Prolonged Inflammation Impairs Wound Healing and Increases Scarring
Researchers used the established rabbit ear hypertrophic scar model for studying the causal effect of dysregulated inflammation. They induced an exacerbated and prolonged inflammatory state in these wounds with the combination of trauma-related stimulators of pathogen-associated molecular patterns from heat-killed Pseudomonas aeruginosa and damage-associated molecular patterns from a dermal homogenate. [Wound Repair Regen] Abstract

SKIN CANCERS & DISORDERS

Filamin A Expression Negatively Regulates Sphingosine-1-Phosphate-Induced NF-κB Activation in Melanoma Cells by Inhibition of Akt Signaling
The authors showed that extracellular sphingosine-1-phosphate (S1P) activates NF-κB only in melanoma cells that lack filamin A. S1P, but not tumor necrosis factor alpha, promoted IKK and p65 phosphorylation, IκBα degradation, p65 nuclear translocation and NF-κB reporter activity. [Mol Cell Biol] Abstract

Acid Ceramidase in Melanoma: Expression, Localization and Effects of Pharmacological Inhibition
Investigators found that acid ceramidase expression is markedly elevated in normal human melanocytes and proliferative melanoma cell lines, compared to other skin cells (keratinocytes and fibroblasts) and non-melanoma cancer cells. [J Biol Chem] Abstract | Full Article

HLA Class I Downregulation Is Associated with Enhanced NK-Cell Killing of Melanoma Cells with Acquired Drug Resistance to BRAF Inhibitors
Scientists asked whether human NK cells can target melanoma cells that have acquired resistance to selective inhibitors targeting activating mutants of the B-Raf kinase (BRAF). All drug-resistant cell variants remained susceptible to lysis by IL-2-activated NK cells; and two BRAF inhibitor-resistant lines became significantly more susceptible to NK-cell lysis than their parental lines. [Eur J Immunol] Abstract

Notch1 Pathway Activity Determines the Regulatory Role of Cancer-Associated Fibroblasts in Melanoma Growth and Invasion
Using a mouse melanoma model in which exogenous melanoma cells were grafted on the skin of two lines of mice where the genetic activation or inactivation of Notch1 signaling specifically occurs in natural host stromal fibroblasts, scientists demonstrated that Notch1 pathway activity could determine the tumor-promoting or tumor-suppressing phenotype in cancer-associated fibroblasts. [PLoS One] Full Article

Visit our reviews page to see a complete list of reviews in the dermal cell research field.

From our sponsor:
Optimize your ALDHbr cell detection with tissue-specific ALDEFLUOR™ protocols. Watch the video.

Array BioPharma and Pierre Fabre Announce Development and Commercialization Collaboration For Two Novel Oncology Products, Binimetinib and Encorafenib
Array BioPharma Inc. and Pierre Fabre announced a collaboration to globally develop and commercialize Array’s late-stage novel oncology products, binimetinib and encorafenib. Binimetinib, a MEK inhibitor, and encorafenib, a BRAF inhibitor, are currently advancing in three, global Phase III trials for melanoma and ovarian cancer. [Array BioPharma Inc.] Press Release

Immune Pharmaceuticals Announces FDA Acceptance of Investigational New Drug (IND) Application in the U.S. for Bertilimumab for the Treatment of Bullous Pemphigoid
Immune Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) accepted the Company’s IND application for its first in class, lead product candidate, Bertilimumab, for the treatment of bullous pemphigoid. [Immune Pharmaceuticals, Inc.] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the dermal cell community.

NEW Team Leader/Professor/Associate Professor – Regenerative Medicine (Ji Nan University)

Computational Biologist – UV Irradiation and Melanoma (Cancer Research UK Manchester Institute)

Research Faculty and Associates – Dermatology (University of Pittsburgh)

Postdoctoral Position – Genetic Skin Diseases (Inserm)

Postdoctoral Associate – Dermatology (University of Pittsburgh)

Research Technician II – Stem Cell and Gene Therapy (Fred Hutchinson Cancer Research Center)

Postdoctoral Position – Tissue Engineering and Regenerative Medicine (Northwestern University)

Postdoctoral Position – Medicinal Chemistry (Auburn University)

Independent Junior Group Leader – Human Genetics of Inflammatory Skin Diseases (University of Lübeck)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.